Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
SOLV · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortSolventum Corp is profitable, burns cash and carries moderate debt, with revenue stable (+0.9% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 26.2% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 18.7% | 95/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 38.9% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 19.6% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.23× | 36/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.00× | 56/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.56× | 70/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.34 | 32/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -0.1% | 20/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -0.01× | 0/100 |
| Years with positive free cash flow (last 5) | 3 of 4 | 69/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 4 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 3 | 100/100 |
| Revenue growth volatility | 0.1% | 100/100 |
| Operating margin volatility | 5.6% | 58/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 0.8% | 21/100 |
|---|---|---|
| EPS growth, 3-year average | 4.5% | 48/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 4 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 8,130 | 8,197 | 8,254 | 8,325 |
| Gross profit | 4,695 | 4,693 | 4,593 | 4,451 |
| Research & development | 767 | 758 | 775 | 739 |
| Selling, general & admin | 2,235 | 2,299 | 2,782 | 3,080 |
| Operating income | 1,693 | 1,692 | 1,036 | 2,181 |
| Pre-tax income | 1,692 | 1,667 | 605 | 1,713 |
| Income tax | 349 | 321 | 127 | 157 |
| Net income | 1,343 | 1,346 | 479 | 1,556 |
| Diluted EPS | $7.78 | $7.79 | $2.76 | $8.88 |
| Diluted shares (millions) | 173 | 173 | 174 | 175 |
2.34 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 5, 2026